No quarterly revenue total was found in Elicio Therapeutics, Inc.'s SEC filings.
Elicio Therapeutics, Inc. (ELTX) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Sep 30, 2026 it held $30.9 million in cash and investments and $14.0 million in total debt.
Revenue
—
Net income
$-7.98M
+20.9% vs year-ago quarter
Operating cash flow
$-10.36M
+6.5% vs year-ago quarter
Free cash flow
$-6.81M
+22.5% vs year-ago quarter
EPS
$-0.30
+50.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
28.31M
+61.9% vs year-ago quarter
Net cash
$16.91M
Q3 FY2026
Operating margin
-2611.5%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ELTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1601485
- Former names
- Angion Biomedica Corp. (until May 30, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$8.5M | -$10.4M | -$10.6M | -$8.8M | -$8.0M |
| Net income | -$8.0M | -$8.2M | -$11.8M | -$7.7M | -$10.1M |
| Diluted EPS | -$0.30 | -$0.43 | -$0.65 | -$0.50 | -$0.60 |
| Operating cash flow | -$10.4M | -$8.2M | -$11.6M | -$6.8M | -$11.1M |
| Free cash flow | — | — | — | -$6.8M | -$11.1M |
| Total assets | $39.6M | $31.3M | $22.7M | $25.9M | $28.3M |
| Total liabilities | $20.7M | $23.4M | $24.1M | $24.2M | $24.5M |
| Stockholders' equity | $18.9M | $7.9M | -$1.4M | $1.6M | $3.8M |
| Cash and investments | $30.9M | $23.5M | $14.9M | $18.6M | $20.6M |
| Total debt | $14.0M | $14.1M | $14.3M | $15.1M | $15.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Other events
|
Sep 14, 2026 | Sep 14, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Jul 2, 2026 | Jul 1, 2026 |
All 384 Elicio Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.